Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Epizyme Emerges From Stealth Mode

This article was originally published in The Pink Sheet Daily

Executive Summary

Tiny start-up aims to be a dominant player in the unfolding field of epigenetics.

You may also be interested in...



Eisai Deal Puts Epizyme In Position To Advance Lead Program

Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.

Eisai Deal Puts Epizyme In Position To Advance Lead Program

Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.

Genentech Exec Heads East To Take The Reins Of Cancer-Focused Start-up Agios

Calling it “the right time and the right opportunity,” Genentech’s cancer drug development expert David Schenkein plans to move on.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel